Company Filing History:
Years Active: 2013
Title: Michael Chastain: Innovator in Antibody Development
Introduction
Michael Chastain is a notable inventor based in Seattle, WA. He has made significant contributions to the field of biomedical research, particularly in the development of antibodies for diagnostic and therapeutic purposes. His work focuses on addressing cellular proliferative disorders, which are critical in the understanding and treatment of various cancers.
Latest Patents
Michael Chastain holds a patent for "IGF-1R specific antibodies useful in the detection and diagnosis of cellular proliferative disorders." This invention relates to mammalian antibodies, designated 12B1, and their antigen-binding portions that specifically bind to the insulin-like growth factor I receptor (IGF-IR), preferably human IGF-IR. The patent also includes chimeric, bispecific, and derivatized single-chain antibodies derived from the disclosed antibodies. Additionally, it covers nucleic acid molecules encoding these mammalian antibodies, as well as methods of use for treatment and diagnosis of pathological hyperproliferative oncogenic disorders associated with IGF-1R expression.
Career Highlights
Michael Chastain is currently employed at Merck Sharp & Dohme Corp., where he continues to advance his research in antibody development. His innovative work has the potential to significantly impact the diagnosis and treatment of various oncogenic disorders.
Collaborations
Michael has collaborated with notable colleagues, including Liliane Goetsch and David Brooks. Their combined expertise contributes to the advancement of research in the field of antibody therapeutics.
Conclusion
Michael Chastain is a prominent inventor whose work in antibody development is paving the way for new diagnostic and therapeutic approaches in oncology. His contributions are vital to the ongoing fight against cancer and related diseases.